[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579758":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":29,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Adult patients with burn injury",null,[12],"Other: Biological sampling",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Biological sampling","Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites)\n\nAt day 0, day 3, day 7, day 14, day 21",[9],[19,25],{"name":20,"role":21,"phone":22,"phoneExt":23,"email":24},"Emmanuel Dudoignon, MD","CONTACT","1 42 49 93 94","+33","emmanuel.dudoignon@aphp.fr",{"name":26,"role":21,"phone":27,"phoneExt":23,"email":28},"Jérôme Lambert, MD PhD","+33142499742","jerome.lambert@u-paris.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Hôpital Saint Louis AP-HP","RECRUITING","Paris","France","FR",{"type":37,"coordinates":38},"Point",[39,40],2.3488,48.85341,{"lat":40,"lon":39},[43],{"name":44,"role":21,"phone":45,"phoneExt":23,"email":24},"Emmanuel Dudoignon","+331 42 49 94 31",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100579758","determining-elements-of-anti-fungal-immunity-in-burn-patients-100579758",false,"NCT06828458","Determining Elements of Anti-Fungal Immunity in BURN Patients","DEFI-BURN","Inclusion Criteria:\n\nBurn patients\n\n* Adult patients ≥ 18 years old\n* Admission \\\u003C 4 days following burn injury\n* Total burn surface Area ≥ 15%\n* Non opposition of the patient or his\u002Fher relatives to the research\n* Affiliation to social security or any health insurance\n\nExclusion Criteria:\n\n* Pregnancy\n* Opposition of the patient or his\u002Fher relatives\n* Decision not to resuscitate or to limit or stop active therapies","ALL","18 Years",{"count":58,"type":59},327,"ESTIMATED","OBSERVATIONAL","Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.",[63],"Burn","2026-04-22",{"date":66,"type":67},"2026-04-23","ACTUAL",{"date":69,"type":67},"2025-04-23",{"date":71,"type":59},"2030-10-23",{"name":5,"class":6},1]